Dave Denton spoke to Crain's about the $43 billion proposed Seagen deal and how the company could fare in the wake of the ...

The U.S. health regulator said on Thursday the current emergency use authorization (EUA) for Pfizer's COVID-19 antiviral pill ...

REUTERS/Carlo Allegri/ (Reuters) - Advisers to the U.S. health regulator on Thursday voted in favor of recommending a full ...

Data from Pfizer Inc's trials of its COVID-19 drug support its use in adults at high-risk of the disease, staff reviewers at ...

The FDA's independent panel of advisors recommended full approval of Pfizer's Covid antiviral treatment Paxlovid for adults who are at high risk of getting severely sick with Covid. The FDA first ...

The Food and Drug Administration yesterday amended its emergency use authorization for Pfizer’s updated COVID-19 vaccine to ...

The U.S. Food and Drug Administration (FDA) has authorized a single booster dose of the Pfizer-BioNTech COVID-19 vaccine bivalent for children six months old through four years of age. At least ...

The new shot is bivalent, meaning it targets the original Covid strain as well as omicron BA.4 and BA.5. Pfizer's primary series for young children consists of three doses, while rival drugmaker ...

Advisers to the U.S. health regulator on Thursday voted in favor of recommending a full approval for Pfizer's COVID-19 pill Paxlovid in adults at high risk of progression to severe disease.

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 ...

The FDA dropped in briefing document as the agency's external advisors meet on Thursday (March 16) to discuss complete ...